Indu Lal

1.2k citations
14 papers · 787 · 1 hit paper · h-index 6

Impact in

  • Genetics top 2%
    • Chronic Lymphocytic Leukemia Research
  • Hematology top 2%
    • Hematopoietic Stem Cell Transplantation
    • Chronic Myeloid Leukemia Treatments

Papers in

    • Chronic Lymphocytic Leukemia Research 12
    • Chronic Myeloid Leukemia Treatments 7
    • Acute Myeloid Leukemia Research 5

Indu Lal

14 papers receiving 776 citations

Hit Papers

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study 2019 · 312 citations
3120+2+4Years since publication100200300

Peers

Indu Lal
Comparison fields: 5 of 46
  • Genetics 518
  • Hematology 372
  • Pathology and Forensic Medicine 338
  • Immunology 290
  • Transplantation 24
Replace Don Milligan with:
Don Milligan United Kingdom
Paul Moreton United Kingdom
Niels Smedegaard Andersen Denmark
Charalampia Kyriakou United Kingdom
Priscille Bourquelot France
Saad M. B. Rassam United Kingdom
SN Rabinowe United States
Carmen Pedro Spain
Aurore Perrot France
H. Löffler Germany
Indu Lal relative to Don Milligan United Kingdom Don Milligan's profile →
Citations per field
00.5×3.5×
Don Milligan · 1×
Citations per year

Countries citing papers authored by Indu Lal

Since Specialization
Citations

This map shows the geographic impact of Indu Lal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Indu Lal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Indu Lal more than expected).

Fields of papers citing papers by Indu Lal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Indu Lal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Indu Lal. The network helps show where Indu Lal may publish in the future.

Co-authors

The 25 scholars most cited alongside Indu Lal, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Indu Lal Line = papers co-authored together Indu Lal links everyone, so they are left out of the graph.

All Works

14 of 14 papers shown
#Work
1
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
Hit paper breakdown →
2019312
2 2017312
3 201966
4 202057
5 201614
6 20229
7 20225
8 20205
9 20222
10 20191
11 20221
12 20221
13 20221
14 20181

About Indu Lal

Indu Lal is a scholar working on Genetics, Hematology, Pathology and Forensic Medicine, Immunology and Public Health, Environmental and Occupational Health, having authored 14 papers that have together received 787 indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (12 papers), Chronic Myeloid Leukemia Treatments (7 papers), Lymphoma Diagnosis and Treatment (5 papers), Acute Myeloid Leukemia Research (5 papers), Immunodeficiency and Autoimmune Disorders (3 papers), Acute Lymphoblastic Leukemia research (3 papers), Phagocytosis and Immune Regulation (2 papers) and Gastrointestinal Tumor Research and Treatment (1 paper). The work is most often cited by research in Genetics (518 citations), Hematology (372 citations), Pathology and Forensic Medicine (338 citations), Immunology (290 citations) and Transplantation (24 citations). Indu Lal has collaborated with scholars based in United States, United Kingdom and Italy. Frequent co-authors include Aaron C. Logan, Samantha Jaglowski, Lori Styles, David B. Miklos, Iskra Pusic, Edmund K. Waller, Mary E.D. Flowers, Madan Jagasia, Mukta Arora and Corey Cutler. Their work appears in journals such as Blood, Biology of Blood and Marrow Transplantation, Leukemia Research, Leukemia and HemaSphere.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact